The TPIRC Difference for OIT...

February 10, 2016

Last month, the FDA released a Briefing Document (link below) outlining a few limitations in the application of the standard clinical trial model to food allergy treatment such as oral immunotherapy (OIT). For example, the FDA notes that “subjecting severely food-allergic individuals … Continue reading

oit_predictors

Thinking about OIT but worried about reactions? Let’s ...

October 18, 2015

After treating nearly 700 food allergy OIT patients, a common theme during initial office visits surrounds not just safety but the “risk of reactions” during OIT. Many parents state their child has not had anaphylaxis for years. Others will say … Continue reading

Patch-vs-TPIRC-OIT-2

The Patch versus TPIRC OIT Model: The Difference is Clear...

October 14, 2015

The Patch vs. TPIRC OIT Model: The Difference is Clear Phase IIB VIPES (Viaskin Peanut’s Efficacy and Safety) trial was conducted in 221 peanut allergy patients (6-55 years with 113 children, 73 adolescents and 35 adults).  The goal of the … Continue reading